AP) - Diversified condition consternation issue maker Abbott Laboratories (NYSE:ABT) said Friday the Chuck and Narcotic Authority approved its fully automated HTLV-I HTLV-II blood screening probation with its Prism instrument. HTLV-I HTLV-II is designed to be cast-off next to labs to shade blood championing antibodies to hominoid T-lymphotropic virus Kind I and II, which are associated with leukaemia and lymphoma.

Abbott's Prism tool is already approved to research representing hepatitis. Division of Abbott flatten 32 cents to hurried at $59.53. Copyright 2007 Associated Press. All rights reserved. This data may not be published, broadcast, rewritten, or redistributed. Marketplace indexes are shown in positive time, apart from for the DJIA, which is delayed close to two minutes. All spell are ET.

Day mirrors community stock exchange trading time. 8224; - Intraday news delayed 15 second for Nasdaq, and 20 split second for other exchanges. Disclaimer Copyright © 2008 BigCharts.com Inc. Humour inspect our Appellation of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday material delayed 15 before you can say 'jack robinson' for Nasdaq, and 20 flash for other exchanges. All Patch are ET.

Historical, now end-of-day data, and splits up info if near FT Interactive Data. Essential facts provided alongside Hemscott. SEC Filings counsel provided beside Edgar Online Inc..

From http://money.cnn.com/news/newsfeeds/articles/newstex/afx-001~.htm